Here’s a breakdown of teh references provided, formatted for clarity:
1. FDA Approval of Enfortumab Vedotin adn Pembrolizumab:
* Source: U.S. Food and Drug Management (FDA)
* Title: FDA Approves Enfortumab Vedotin-ejfv and Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
* Date Accessed: Not explicitly stated, but likely current as of the document’s creation.
* the references relate to advancements in bladder cancer treatment, specifically the combination of Enfortumab Vedotin and pembrolizumab.
* There’s a mix of primary research (the NEJM publication), regulatory information (the FDA approval), news reporting (Axios), and industry press releases.
* The date of access for the press release is the same as the release date, suggesting it was accessed immediately upon publication.
* The Axios article addresses a broader issue of chemotherapy drug shortages, which is relevant to cancer care in general.
